ImmuCell(US:ICCC)2026-01-08 21:13Sales Performance - Total sales for Q4 2025 were $7.6 million, a 1.6% decline from Q4 2024 sales of $7.8 million[4] - Total sales for the full year 2025 were $27.6 million, a 4.3% increase compared to 2024 sales of $26.5 million[4] - Domestic sales in 2025 were $24.4 million, a 6.5% increase from 2024[6] - International sales in 2025 were $3.3 million, a 9.6% decline compared to 2024[6] - Tri-Shield® sales reached $19.9 million in 2025, a 26.5% increase from 2024[6] - Dual-Force® and other sales were $7.7 million in 2025, a 28.2% decline compared to 2024[6] Financial Adjustments - The company plans to record a $2.9 million non-cash impairment write-down related to Re-Tain® during Q4 2025[4] Operational Improvements - Manufacturing improvements increased output of the lyophilization process by over 15% year-over-year in 2025[5] Strategic Initiatives - The company is expanding its sales force by 50% by creating two new domestic territories and hiring an international business development executive[8] - The company intends to focus on commercial expansion and scalable manufacturing capacity to support growth in the First Defense® product line[8]